Gastro intestinal cancer trang 1 tải miễn phí từ TAILIEUCHUNG

"Gastro intestinal cancer" trang 1 - tải miễn phí từ Tailieuchung

Relevance of internal time and circadian robustness for cancer patients

Relevance of internal time and circadian robustness for cancer patients

12 57 1

Incidence and time trends of sarcoma (2000–2013): Results from the French network of cancer registries (FRANCIM)

Incidence and time trends of sarcoma (2000–2013): Results from the French network of cancer registries (FRANCIM)

11 62 0

Vulnerability in elderly patients with gastrointestinal cancer – translation, cultural adaptation and validation of the European Portuguese version of the Vulnerable Elders Survey (VES-13)

Vulnerability in elderly patients with gastrointestinal cancer – translation, cultural adaptation and validation of the European Portuguese version of the Vulnerable Elders Survey (VES-13)

10 45 1

Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development

Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development

10 23 1

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

14 54 1

The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers

The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers

9 26 1

Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT

Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT

4 30 1

The off-label use of targeted therapies in sarcomas: The OUTC’S program

The off-label use of targeted therapies in sarcomas: The OUTC’S program

11 33 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.